


Technology Advisory Interests Register

Topic: enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy [ID6332]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC Committee Member	Direct- financial	Michael has participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer	06/02/2025	It was agreed that Michael's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Direct- financial	Kate provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	06/02/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Direct- financial	Elizabeth is currently working with Pfizer, in unrelated indication, NSCLC.	07/02/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Stella O'Brien	TAC Committee Member	Indirect - Professional	Stella is a member of NHSE's Cancer Genomics Test Evaluation Working Group. They consider tests for addition to the National Genomic Test Directory. She does not receive any honoraria or other direct/indirect reward for this activity.	06/02/2025	It was agreed that Stella's declaration would not prevent them from participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases. It already has cemiplimab, a PD1 inhibitor licensed for a variety of indications and being developed for several other tumour types/malignancies including genitourinary cancers. Satish works for Regeneron, pharmaceuticals/biotech company. He also owns shares in the company and have stock options.	07/02/2025	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal
Syed Hussain	Clinical Expert	Direct- financial	Syed has the below financial interests to declare: • Research funding: CR UK, MRC/NIHR, UHB charities, CCC charities, Northwest Cancer Research, Yorkshire Cancer Research, Weston Park cancer	21/08/2024	It was agreed that Syed's declaration would not prevent them from providing expert advice to the committee



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			charity, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly • Advisory board/Consultancy: Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Merck, Pierre Fabre, Ipsen, Sotio, Eisai, Gilead. • Astellas; Advisory board and consultancy meetings £3120. Chairing and contributing to the advisory board meeting. Pre-meeting paperwork completion. Discussed the clinical trial data EV-302. Discussed the changing landscape of advanced urothelial cancer and advised the industry about positioning of EV plus Pembrolizumab.		
Robert Huddart	Clinical Expert	Direct- financial Indirect – non- financial	Robert has treated a limited number of patients in private sector with this technology. Robert has co-authored the European Society of Medical Oncology guidelines on the	31/01/2025	It was agreed that Robert's declaration would not prevent them from providing expert advice to the committee



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			management of metastatic bladder		
			cancer including current technology		

